<DOC>
	<DOCNO>NCT02144194</DOCNO>
	<brief_summary>This 2 arm study assess efficacy safety Vinorelbine-Docetaxel combination give initial upfront treatment ( first line ) metastatic breast cancer patient enrol . Patients disease control follow initial treatment , randomize either oral Vinorelbine maintenance arm Observation arm . The trial also compare efficacy safety maintenance oral Vinorelbine versus Observation .</brief_summary>
	<brief_title>Maintenance Oral Vinorelbine Observation After Vinorelbine-Docetaxel First Line Chemotherapy Advanced Breast Ca</brief_title>
	<detailed_description>To knowledge , first trial evaluate role oral Vinorelbine maintenance therapy versus observation follow first line treatment iv/oral Vinorelbine+Docetaxel . Eligible patient enrol trial receive 6 cycle iv ( D1 ) /oral ( D8 ) Vinorelbine + Docetaxel . For respond SD patient , 6 cycle , randomize either observation arm receive maintenance chemotherapy oral Vinorelbine . The oral form drug find appropriate long term treatment allow preserve QoL patient . Oral Vinorelbine administer D1 , D8 every 3 week maintenance treatment , PD , unacceptable toxicity patient refusal continue . The trial ass efficacy/safety initial Vinorelbine-Docetaxel combination well benefit maintenance chemotherapy oral Vinorelbine .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Written inform consent Patients &gt; =18 year age Histologically cytologically confirm adenocarcinoma breast metastatic locallyrecurrent inoperable curative intent Measurable and/or nonmeasurable disease The patient 's primary and/or metastatic tumor HER2 neu negative Documented metastatic disease previously untreated palliative chemotherapy Adjuvant neoadjuvant chemotherapy ( include treatment docetaxel chemotherapy ) allow disease free survival least 6 month No symptom sign brain metastasis Operable local recurrence Ascites pericardial effusion site metastasis Symptomatic peripheral neuropathy &gt; grade 1 accord NCI Common Toxicity Criteria Radiotherapy area evaluable disease within previous 4 week Disease significantly affect absorption Severe hepatic insufficiency Patient previously treat chemotherapy metastatic disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Oral Vinorelbine</keyword>
	<keyword>Oral Chemotherapy</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Advanced Breast Cancer</keyword>
	<keyword>Maintenance treatment</keyword>
</DOC>